{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Investigational
Source:
NCT00695851: Phase 1 Interventional Completed Prostate Cancer
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tigapotide (also known as PCK3145) is a synthetic peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the prostate is downregulated in patients with advanced prostate cancer and believed to be a survival mechanism for the cancer cells. Tigapotide can exert anticancer activity not only on prostate but also on breast and colon cancer cells, possibly through laminin receptor-mediated activation of MEK and ERK1/2 phosphorylation. However, the exact molecular mechanisms of action of Tigapotide against prostate cancer tumor growth and metastasis, and tumor-associated angiogenesis remain poorly understood. In preclinical trials, Tigapotide shows potent anticancer activity and reduces prostate cancer growth in PC3 xenograft mouse model and the Dunning rat R-3327 MLL model. Phase II a clinical trial results with Tigapotide confirmed its therapeutic safety and tolerability for metastatic hormone-refractory prostate cancer. This effect was in part correlated to a marked reduction in the high levels of plasma MMP-9, a gelatinase B enzyme involved in extracellular matrix degradation and tumor invasion, of patients receiving Tigapotide, suggesting a biological effect possibly related to control metastasis.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Semparatide (previously known as RS-66271) was developed as an analog of parathyroid hormone-related protein (PTHrP) with shortening the time for fracture healing. Experiments on animals have shown that this compound was an effective therapy for preventing impaired bone healing caused by prednisone. Clinical trials with postmenopausal osteoporotic women have revealed that semparatide cause sustained increases in the spine. However, further, development appears to have been discontinued by Roche.
Status:
Investigational
Source:
INN:ratangratinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:taragarestrant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:tasipimidine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03396068: Phase 3 Interventional Active, not recruiting Bipolar Depression
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT01597739: Phase 2 Interventional Completed Arthritis, Rheumatoid
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04331730: Phase 2 Interventional Completed Neovascular Age-related Macular Degeneration
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00920205: Phase 1 Interventional Completed Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor developed by Myriad Pharmaceuticals, Inc for cancer treatment. MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. MPC-3100 shows a broad spectrum anti-proliferative activity against various cancer cell lines, such as HCT-116, NCI-N87 and DU-145. MPC-3100 also inhibits tumor growth in the NCI-N87 gastric cancer xenograft mode. Moreover, pharmacokinetics studies show that MPC-3100 displays a superior oral pharmacokinetics profile, good overall exposure and a reasonable hepatic clearance rate. Phase I clinical studies demonstrate MPC-3100 is safe and tolerated when administered at doses below 600 mg per day
